Abstract

Serum Branched Chain Amino Acids May Determine the Severity of Coronary Artery Disease as Evidenced by Regression Modelling Ahsan Mushtaq

Highlights

  • The objective of this study was to observe the effects of low-molecular-weight heparin calcium (LMWHC) combined with argatroban on the treatment, vascular endothelial function, inflammatory factors and neurological function in patient with acute cerebral infarction

  • Recent years witnessed its investigates the actual efficacy of low-molecular-weight occurrence in younger population. It can occur at any heparin calcium (LMWHC) combined with argatroban in age with no specific morbidity group, and there is no the treatment of ACI, and determines the basic mechanism forewarning at the time of onset

  • It does not affect vascular permeability when it exists in the form of calcium salt, and can play a role in improving cerebral hemodynamics and producing antithrombotic effects, but it is not ideal for the treatment of progressive cerebral infarction when used alone, so its combined use with other anticoagulant drugs in clinical application is currently the main treatment strategy (Arahata and Asakura, 2018; Zhu et al, 2018)

Read more

Summary

Introduction

The objective of this study was to observe the effects of low-molecular-weight heparin calcium (LMWHC) combined with argatroban on the treatment, vascular endothelial function, inflammatory factors and neurological function in patient with acute cerebral infarction. We conclude that LMWHC combined with argatroban are safe and effective in the treatment of acute cerebral infarction. Authors’ Contribution X Yao and GZ collected the samples, conducted the experiments and analysed the results. Recent years witnessed its investigates the actual efficacy of low-molecular-weight occurrence in younger population. It can occur at any heparin calcium (LMWHC) combined with argatroban in age with no specific morbidity group, and there is no the treatment of ACI, and determines the basic mechanism forewarning at the time of onset. Days of treatment, intravenous infusion of 10mg argatroban was given, 2 times a day and 3 h per time

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.